ANI Pharmaceuticals (ANIP) Projected to Post Earnings on Friday

ANI Pharmaceuticals (NASDAQ:ANIP) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Friday, August 8th. Analysts expect the company to announce earnings of $1.49 per share and revenue of $187.18 million for the quarter. ANI Pharmaceuticals has set its FY 2025 guidance at 6.270-6.620 EPS.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a positive return on equity of 21.35% and a negative net margin of 3.12%. The firm had revenue of $197.12 million for the quarter, compared to analysts’ expectations of $179.75 million. During the same quarter last year, the firm earned $0.82 earnings per share. The firm’s revenue for the quarter was up 43.4% compared to the same quarter last year. On average, analysts expect ANI Pharmaceuticals to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $69.09 on Thursday. The firm has a market cap of $1.50 billion, a P/E ratio of -54.40 and a beta of 0.61. The stock has a 50-day simple moving average of $64.53 and a 200-day simple moving average of $63.59. ANI Pharmaceuticals has a 1 year low of $52.50 and a 1 year high of $77.00. The company has a debt-to-equity ratio of 1.46, a quick ratio of 1.98 and a current ratio of 2.66.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wall Street Zen cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, April 24th. Truist Financial increased their target price on ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a “hold” rating in a report on Monday, April 21st. Guggenheim restated a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, HC Wainwright initiated coverage on shares of ANI Pharmaceuticals in a research note on Thursday, July 10th. They issued a “buy” rating and a $84.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $78.88.

Insider Activity at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $64.88, for a total value of $25,952.00. Following the transaction, the vice president directly owned 78,945 shares in the company, valued at $5,121,951.60. This represents a 0.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Christopher Mutz sold 4,000 shares of the firm’s stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $60.45, for a total value of $241,800.00. Following the completion of the transaction, the insider owned 107,317 shares in the company, valued at $6,487,312.65. This represents a 3.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,681 shares of company stock valued at $345,222 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter worth about $2,706,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in ANI Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,993 shares of the specialty pharmaceutical company’s stock valued at $736,000 after buying an additional 470 shares during the period. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the first quarter valued at $28,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of ANI Pharmaceuticals by 0.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock worth $3,235,000 after acquiring an additional 423 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.